OptiNose(OPTN) - 2023 Q3 - Earnings Call Presentation

Financial Performance & Guidance - Q3 2023 XHANCE net revenues reached $198 million[18], supporting an increase to FY 2023 expectations[18] - Full Year 2023 XHANCE net revenues are expected to be between $66 million and $70 million[1, 48] - SG&A plus R&D expenses decreased by approximately $9 million from Q3 2022 to Q3 2023[18] - Year-to-date September 2023 XHANCE net revenues totaled $511 million[45, 59], exceeding initial expectations[59] - Year-to-date September 2023 SG&A plus R&D expenses decreased by approximately $32 million compared to the same period in 2022[59] - The company held $668 million in cash as of September 30, 2023[36] Prescription Trends - Q3 2023 total XHANCE prescriptions reached 841 thousand[16] - Q3 2023 new XHANCE prescriptions reached 274 thousand[16], a decrease of 4%[31] - Year-to-date September 2023 total XHANCE prescriptions reached 2600 thousand[26], an increase of 1%[58] - Year-to-date September 2023 new XHANCE prescriptions reached 888 thousand[26], an increase of 1%[58] Clinical & Regulatory Updates - The FDA accepted the supplemental new drug application (sNDA) for review, targeting a new indication[14] - The PDUFA target action date for the sNDA is December 16, 2023[14]